About the Webinar
The discovery and advancements of nucleases, including CRISPR-Cas9, have revolutionized the accuracy and downstream potential of targeted genomic manipulations. Despite these advancements, identification of correctly targeted events remains a significant bottleneck. Simple, fast, and cost-effective techniques, such as RFLP and Sanger sequencing, have traditionally been used for screening. However, both techniques lack sensitivity and scalability. Next generation sequencing provides ultra-sensitive results, but requires extensive bioinformatics expertise to interpret data. Furthermore, scalability was mitigated by limitations in off-the-shelf library preparation kits. This webinar will describe the differences amongst various screening techniques and focus on recent advancements in the utility of next generation sequencing.
About the Presenter
.png?width=159&name=chris_(3).png)
Chris Mozdzierz earned his Ph.D. in Molecular Genetics from Rutgers University where he studied the application of bacterial toxin systems for novel cancer therapeutics. After graduating and a short postdoc, Chris joined Roche Pharmaceuticals where he utilized NGS to help solve biological questions across a myriad of disease target areas. Chris currently works as the Manager of the NGS department at GENEWIZ where his main responsibilities are customer support, business development, and business operations.
